News centre

Health Canada Authorizes TECVAYLI^TM (teclistamab injection), a First-in-Class Bispecific Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Approval for TECVAYLI^TM, a subcutaneously administered therapy, is based on results from the Phase 1/2 MajesTEC-1 study that showed deep and durable responses in triple-class exposed patients with relapsed or refractory multiple myeloma.¹

21 August, 2023

News centre

Health Canada Authorizes AKEEGA^TM (niraparib and abiraterone acetate) Dual Action Tablets for Targeted Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with BRCA (1/2) Gene Mutations

Approval for AKEEGA^TMis based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated metastatic castration-resistant prostate cancer (mCRPC)^1,2

Niraparib in combination with abiraterone acetate plus prednisone or prednisolone (AAP), showed significant improvement in radiographic progression-free survival (rPFS) compared to AAP in mCRPC patients with BRCA1/2 mutations³

15 June, 2023

News centre

RYBREVANT^® (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations

11 April, 2023

News centre

Health Canada Authorizes IMBRUVICA^® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

All-oral, once-daily, fixed-duration combination regimen authorized for first-line treatment of CLL

24 March, 2023

Search Results

No Results

Recently Viewed

News centre

Latest press releases